Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
CONCLUSION: The response rates and overall survival of patients with NSCLC, renal carcinoma and triple negative breast cancer of good performance status receiving anti-PD-1 therapy outside of a clinical trial are consistent with clinical trial data. However, patients with poor ECOG performance status are unlikely to respond. Careful patient selection and counseling about the potential outcomes of self-funding treatment in this setting is needed.
PMID: 29498208 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tiu C, Wong A, Herschtal A, Mileshkin L Tags: Asia Pac J Clin Oncol Source Type: research
More News: Australia Health | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Gastroenterology | Immunotherapy | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Nonmelanoma Skin Cancer | Skin Cancer | Toxicology